文献速递造血干细胞移植与细胞治疗

慢性移植物抗宿主病患者血清特异性生物标志物的临床观察

[The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

本研究采用液相悬浮芯片法检测异基因造血干细胞移植后发生与未发生cGVHD患者5种血清蛋白标志物(IL-1b、IL-16、CXCL9、CCL19、CCL17)的表达水平。结果显示cGVHD患者血清CXCL9、CCL17显著升高,CCL17与疾病严重程度相关,CXCL9在皮肤损害患者中显著升高,CCL17在肝脏靶器官患者中显著升高。结论提示CXCL9联合CCL17可作为cGVHD血清生物标志物。

要点

  • cGVHD患者血清CXCL9、CCL17表达水平显著升高
  • CCL17与cGVHD疾病严重程度相关
  • CXCL9联合CCL17可辅助cGVHD诊断和严重程度评估

核心结论

  • CXCL9联合CCL17可作为cGVHD的血清生物标志物,对辅助诊断和评估严重程度有一定参考价值。

研究设计与样本

  • 采用液相悬浮芯片法检测接受异基因造血干细胞移植后发生和未发生cGVHD患者5种血清蛋白标志物(IL-1b、IL-16、CXCL9、CCL19、CCL17)表达水平。

主要发现

  • 相较于未发生cGVHD的对照组,cGVHD患者血清中CXCL9、CCL17表达水平显著升高(P<0.05)。
  • CCL17与cGVHD的疾病严重程度相关(P<0.001)。
  • CXCL9在皮肤损害的cGVHD患者血清中显著升高(P<0.01)。
  • CCL17在肝脏为靶器官的cGVHD患者中表达水平显著升高(P<0.01)。

临床怎么用

  • 可联合检测血清CXCL9与CCL17辅助cGVHD诊断。
  • CCL17水平有助于评估cGVHD严重程度。
  • 皮肤损害患者关注CXCL9,肝脏靶器官患者关注CCL17。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Chronic graft-versus-host disease (cGVHD) is a major long-term complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . It is important to study the changes of serum biomarkers expression in patients for early diagnosis and treatment. Methods: The expression levels of five serum protein markers (IL-1b, IL-16, CXCL9, CCL19, CCL17) in patients with or without cGVHD after allo-HSCT were detected by liquid suspension microarray. Results: Compared with the control group without cGVHD, the expression levels of CXCL9 and CCL17 in serum of patients with cGVHD were significantly increased (P<0.05) . CCL17 was correlated with the severity of cGVHD (P<0.001) . CXCL9 was significantly increased in the serum of patients with skin lesion (P<0.01) , and CCL17 was significantly expressed in cGVHD patients with liver as the target organ (P<0.01) . Conclusion: The combination of CXCL9 and CCL17 can be used as serum biomarkers of cGVHD, which has certain reference value in assisting the diagnosis and evaluation of cGVHD severity. 目的: 研究异基因造血干细胞移植后患者血清生物标志物表达水平对慢性移植物抗宿主病(cGVHD)早期诊断的价值。 方法: 采用液相悬浮芯片法检测接受异基因造血干细胞移植后发生和未发生cGVHD患者5种血清蛋白标志物(IL-1b、IL-16、CXCL9、CCL19、CCL17)表达水平。 结果: 相较于未发生cGVHD的对照组,cGVHD患者血清中CXCL9、CCL17表达水平显著升高(P<0.05),其中CCL17与cGVHD的疾病严重程度相关(P<0.001);CXCL9在皮肤损害的cGVHD患者血清中显著升高(P<0.01),CCL17在肝脏为靶器官的cGVHD患者中表达水平显著升高(P<0.01)。 结论: CXCL9联合CCL17可作为cGVHD的血清生物标志物,对辅助cGVHD诊断和评估严重程度有一定参考价值。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chen T, Li XP, Zhang C, et al. [The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31856446. doi:10.3760/cma.j.issn.0253-2727.2019.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。